DURECT Corporation Announces Positive Results from the Phase 2a Clinical Trial of DUR-928 in Alcoholic Hepatitis Patients in a Late-Breaking Presentation at The Liver Meeting®
Live Webcast of Data Presentation and Discussion by KOL, Tarek I. Hassanein, M.D. at Noon ET on Tuesday, November 12, 2019
CUPERTINO, Calif., Nov. 12, 2019 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced the results from its Phase 2a clinical trial of DUR-928 in alcoholic hepatitis (AH), presented as a late-breaking oral presentation at The Liver Meeting®. The study results were also selected for inclusion in the ‘Best of The Liver Meeting’ summary slide presentation in the alcohol-related liver disease category. Today at Noon Eastern Time, DURECT will host a Key Opinion Leader (KOL) webcast featuring a presentation of the results delivered by one of the principal investigators of the trial, Tarek Hassanein, M.D. Dr. Hassanein will be available for a question and answer session following the presentation.
Results All patients treated with DUR-928 in this trial survived the 28-day follow-up period and there were no drug-related serious adverse events. Patients treated with DUR-928 had a statistically significant reduction from baseline in bilirubin at day 7 and 28 and MELD at day 28. Lille scores were also statistically significantly lower than those from a well-matched group of patients in a contemporary ongoing trial as well as several published historical controls. 74% of all DUR-928 treated patients and 67% of those with severe AH were discharged from the hospital within four days of receiving a single dose of DUR-928.
“The results of this study are remarkable and much was learned from this Phase 2a clinical trial,” stated Dr. Tarek Hassanein, a principal investigator in the trial. “The low Lille scores, the early reduction in bilirubin and the number of severe AH patients who were able to be discharged after a single dose of DUR-928 is striking and the safety profile looks very promising as well.”
Lille Lille scores are used in clinical practice to help determine the prognosis and response of AH patients after seven days of treatment. The lower the Lille score, the better the prognosis. Patients with a Lille score below 0.45 have a six-month survival rate of 85% compared to those with Lille scores above 0.45, with only a 25% six-month survival rate. The chart below shows the Lille scores for individual AH patients treated with DUR-928 plotted as a function of their baseline MELD scores. In our study, the median Lille score for patients treated with DUR-928 was 0.10. The median Lille score among a cohort of 15 patients treated with standard of care at the University of Louisville (UL) was 0.41 (shown as historical control).
The chart below shows individual patient Lille scores plotted as a function of their baseline MELD scores.
Our advisor, Dr. Craig McClain from the University of Louisville (UL), shared anonymized data from his study, in which 15 AH patients with initial MELD scores ranging from 15-30 received either supportive care alone (n=8 moderate AH patients) or supportive care with corticosteroids (n=7 severe AH patients). Two of these patients died by day 28.
One patient in the DUR-928 group did not return for the day 7 visit.
Lille scores in the DUR-928 patients were significantly lower than that of the UL patients (p=0.01; Wilcoxon’s Rank Sum Test).
As shown below, 100% of patients in the 30mg and 90mg DUR-928 dosing groups were treatment responders based on their Lille scores. 89% of the overall DUR-928 patient population were treatment responders. Patients with severe AH, as defined by Maddrey’s Discriminant Function >32 or MELD 21-30, and baseline serum bilirubin above 8 mg/dL, had similarly high response rates to DUR-928 treatment.
AH Patient Category
30 or 90mg DUR-9283
0.10 (0.04, 0.20)
0.05 (0.04, 0.19)
30 or 90mg DUR-9283
0.19 (0.05, 0.22)
0.12 (0.05, 0.19)
30 or 90mg DUR-9283
0.19 (0.11, 0.25)
0.19 (0.10, 0.19)
Baseline bilirubin >8mg/dl2
30 or 90mg DUR-9283
0.10 (0.05, 0.20)
0.10 (0.05, 0.19)
1 One patient did not return for Day 7 visit; 2 Including patients receiving 30, 90 and 150mg of DUR-928; 3 Excluding patients receiving 150mg of DUR-928.
Maddrey’s Discriminant Function (DF) is calculated using the patient’s prothrombin time and serum bilirubin level.
The Lille scores of patients treated with DUR-928 in this trial were also significantly lower than several selected published historical studies (Hepatology 2007, 45:1348-1354; Gut 2011, 60:255-260), in which patients had similar baseline bilirubin, albumin, Creatinine, prothrombin time and DF scores, and were treated with standard of care with or without corticosteroids. Of course, due to the historical nature of these studies, such comparisons should be taken cautiously.
A sub-group analysis was conducted to compare severe AH patients in the 30mg and 90mg dosing groups (n=8) with well-matched severe AH patients (n=13) who received corticosteroids for 28 days in a contemporaneous study at the University of Louisville (UL). Patients shown below in the UL steroid group had a mean baseline MELD of 24.46 and mean Maddrey’s DF score of 62.98. The 8 patients in the DUR-928 group had baseline mean MELD of 24.50 and mean Maddrey’s DF score of 61.25. All patients treated with DUR-928 survived the 28-day follow up period, while 3 patients in the UL steroid group died within the first 28 days.
The steroid group in the above graph includes the 7 severe AH patients treated with steroids from the UL group shown in the MELD vs Lille graph above plus an additional 6 severe AH patients subsequently treated in the UL study.
Bilirubin Bilirubin is formed by the breakdown of red blood cells in the body. The level of total bilirubin in the blood is an indication of how the liver is functioning. In this trial, patients treated with DUR-928 had a significant early reduction from baseline in bilirubin by day 7. Patients with more elevated bilirubin at baseline (serum bilirubin >8 mg/dL) had a median reduction from baseline of 25% by day 7 and 48% by day 28.
*p<0.05 compared to baseline (Wilcoxon’s Signed Rank Test)
Model of End-Stage Liver Disease (MELD) MELD is another common scoring system used to assess the severity and prognosis of AH patients. Patients with MELD scores of 11-20 are classified as having moderate AH and patients with MELD scores of 21-30 are classified as having severe AH. As with Lille scores, the lower the MELD score, the better the prognosis for the AH patient. In this study (shown in the chart below), the median reduction from baseline in MELD among all DUR-928 treated patients was over 2 points and among those with baseline bilirubin levels >8 mg/dL was 5 points by day 28.
*p<0.05 compared to baseline (Wilcoxon’s Signed Rank Test)
MELD is calculated based on (a) bilirubin, (b) serum creatinine (sCr), and (c) International Normalized Ratio (INR), which is a measure of prothrombin time.
Safety and Pharmacokinetics DUR-928 was well tolerated at all doses tested. There were no drug-related serious adverse events and only three adverse events designated as possibly related to DUR-928: one occurrence of moderate generalized pruritus, one mild rash and one grade two alkaline phosphatase. There were no discontinuations, early withdrawals or termination of study drug or study participation due to adverse events. All patients treated with DUR-928 survived through the 28-day follow-up period. Drug exposures were dose proportional and were not affected by the severity of the disease.
About the DUR-928 Alcoholic Hepatitis Phase 2a Trial The open-label, dose escalation, multi-center study was designed to determine the safety, pharmacokinetics and pharmacodynamics of DUR-928 in AH patients following treatment. This included assessing liver biochemistry, biomarkers, and prognostic scores such as the Lille score. Final enrollment included 19 patients with moderate and severe AH, who were administered DUR-928 intravenously at three different doses. Eight patients (four moderate and four severe) were dosed at 30mg, seven patients (three moderate and four severe) were dosed at 90mg and four patients (all severe) were dosed at 150mg. After being discharged on day two, one patient did not return for the scheduled day seven and day 28 follow-up visits; therefore Lille, bilirubin and model of end-stage liver disease (MELD) data reported above are based on 18 patients.
Next Steps DURECT is planning to conduct a double-blind, placebo-controlled, Phase 2b clinical trial evaluating DUR-928 in AH patients beginning mid-2020. Assuming reasonable enrollment rates, top line data from this trial would be available in 2022.
Conference Call and Webcast with Slides
Tuesday, November12 at Noon Eastern Time/9:00 a.m. Pacific Time Dial-In and Webcast Information Tuesday, November 12 at 12 noon EST Domestic (Free): 1-877-407-0784 Toll / International: 1-201-689-8560 Conference ID: 13696593 Webcast with slides: http://public.viavid.com/index.php?id=137023
A replay of the webcast and data slide presentation will be available on the Investor section of the DURECT website at https://investors.www.durect.com/ after the call.
About Dr. Tarek I. HassaneinDr. Hassanein is one of the investigators of the Phase 2a AH clinical trial and is board-certified in internal medicine, gastroenterology and transplant hepatology. He is currently a professor of medicine and director of outreach services for liver transplantation at the School of Medicine, University of California San Diego (UCSD). He has been instrumental in establishing three major liver transplantation programs. Dr. Hassanein established the Southern California Liver Centers in 2009 to care for patients with advanced and complicated liver diseases, including alcoholic hepatitis, liver cancer, HCV and cirrhosis. He is also the director of the Southern California Research Center, medical director of UCSD Sharp Liver Transplant Outreach Program and chief of gastroenterology and hepatology at Sharp Coronado Hospital in Coronado, California. Dr. Hassanein has been the principal investigator on multiple international trials and has authored numerous publications. Dr. Hassanein earned his medical degree from Alexandria University in Alexandria, Egypt. He completed his residency training at Wayne State University in Detroit, Michigan, and a research fellowship and a clinical fellowship in gastroenterology, hepatology and transplantation at the University of Pittsburgh School of Medicine.
About Alcoholic Hepatitis (AH) AH is an acute form of alcoholic liver disease (ALD), associated with long-term heavy intake of alcohol, and often occurs after a recent period of increased alcohol consumption. AH is typically characterized by recent onset jaundice and hepatic failure. An analysis of 77 studies published between 1971 and 2016, which included data from a total of 8,184 patients, showed the overall mortality from AH was 26% at 28 days. According to the most recent data provided by the Agency for Healthcare Research and Quality (AHRQ), a part of the US Department of Health and Human Services (HHS), there were over 117,000 hospitalizations for patients with alcoholic hepatitis in 2016. From a recent publication analyzing the mortality and costs associated with alcoholic hepatitis, the cost per patient is estimated at over $50,000 in the first year. ALD is one of the leading causes of liver transplants in the U.S., each of which costs over $800,000.
About DURECT Corporation DURECT is a biopharmaceutical company actively developing therapeutics based on its Epigenetic Regulator Program and proprietary drug delivery platforms. DUR‑928, a new chemical entity in Phase 2 development, is the lead candidate in DURECT’s Epigenetic Regulator Program. An endogenous, orally bioavailable small molecule, DUR-928 has been shown in preclinical studies to play an important regulatory role in lipid homeostasis, inflammation, and cell survival. Human applications may include acute organ injury such as AH and acute kidney injury (AKI), chronic hepatic diseases such as NASH, and inflammatory skin conditions such as psoriasis and atopic dermatitis. DURECT’s advanced oral and injectable delivery technologies are designed to enable new indications and enhanced attributes for small-molecule and biologic drugs. Key product candidates in this category include POSIMIR® (bupivacaine extended-release solution), an investigational locally-acting, non-opioid analgesic intended to provide up to 3 days of continuous pain relief after surgery, and a long-acting injectable SABER-based HIV investigational product being developed with Gilead. For more information about DURECT, please visit www.www.durect.com.
DURECT Forward-Looking Statement The statements in this press release regarding the potential benefits and uses of DUR-928 to treat AH and about other potential uses of DUR-928 to treat renal diseases, such as NASH and AKI, and inflammatory skin conditions such as psoriasis and atopic dermatitis, the potential use of POSIMIR to treat post-operative pain, and the potential development of a long-acting injectable SABER-based HIV product with Gilead are forward-looking statements involving risks and uncertainties that can cause actual results to differ materially from those in such forward-looking statements. Potential risks and uncertainties include, but are not limited to, the risk of delays in clinical trials or adverse safety events from patients administered with DUR-928, the risk that the ongoing clinical trials of DUR-928 in NASH or psoriasis do not successfully achieve their endpoints, the risk that placebo controlled studies of DUR-928 required for regulatory approval will not replicate results from open label clinical trials or trials with small numbers of patients or historical controls, the risk that reductions in bilirubin, Lille scores or MELD scores do not predict efficacy of therapy for AH, the risks that the long-acting injectable SABER-based HIV investigational product being developed with Gilead will not succeed or that Gilead will abandon this program, the risk that the FDA Advisory Committee will not recommend approval of POSIMIR or that the FDA will not approve POSIMIR, and the risk of delays and costs due to additional work or other requirements imposed by regulatory agencies for continued development, approval or sale of any of our product candidates. Further information regarding these and other risks related to DURECT is included in DURECT’s Form 10-Q filed on November 5, 2019 under the heading “Risk Factors” and in subsequent reports that we file with the Securities and Exchange Commission.
NOTE: POSIMIR® and SABER® are trademarks of DURECT Corporation. Other referenced trademarks belong to their respective owners. DUR-928 and POSIMIR are drug candidates under development and have not been approved for commercialization by the U.S. Food and Drug Administration or other health authorities.
Corporate Contact: Mike Arenberg, DURECT, Chief Financial Officer, +1-408-346-1052, firstname.lastname@example.org, OR Media Contact: Alison Chen, LifeSci Public Relations, +1-646-876-4932, email@example.com
Scroll to Top
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
The _ga cookie, installed by Google Analytics, calculates visitor, session and campaign data and also keeps track of site usage for the site's analytics report. The cookie stores information anonymously and assigns a randomly generated number to recognize unique visitors.
This cookie is installed by Google Analytics.
1 year 27 days
Used by Motomo Analytics to store a few details about the user such as the unique visitor ID.
Short lived cookies used by Motomo Analytics to temporarily store data for the visit.